Humatrope (Somatropin)

Humatrope is indicated for several conditions associated with insufficient endogenous growth hormone.

• Treatment of growth hormone deficiency in children
• Treatment of growth hormone deficiency in adults
• Management of Turner syndrome related short stature
• Management of growth failure in Prader‑Willi syndrome
• Therapy for chronic renal failure associated growth failure
• Treatment of idiopathic short stature in children

• Humatrope delivers recombinant somatropin, which binds to growth hormone receptors on target cells, activating the JAK2‑STAT5 signaling cascade. This stimulates hepatic production of insulin‑like growth factor‑1 (IGF‑1) and promotes anabolic effects on bone, cartilage, and muscle, thereby supporting linear growth and protein synthesis.

Humatrope may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common

• Injection‑site pain or erythema
• Headache
• Joint or muscle stiffness
• Peripheral edema, especially of the hands and feet
• Abdominal discomfort
• Mild hyperglycemia or elevated fasting glucose

Serious

• Intracranial hypertension (increased intracranial pressure)
• Slipped capital femoral epiphysis
• Severe allergic reactions, including anaphylaxis
• Worsening of glucose intolerance or new‑onset diabetes
• Potential acceleration of tumor growth in patients with active malignancy

Before initiating Humatrope therapy, clinicians should evaluate several safety considerations.

• Do not use in patients with active malignancy or a history of cancer recurrence
• Monitor blood glucose levels regularly, especially in diabetic or pre‑diabetic individuals
• Assess for signs of intracranial hypertension, such as headaches or visual changes
• Adjust dosing in patients with severe renal impairment
• Discontinue if a hypersensitivity reaction to somatropin or any excipient occurs
• Pregnancy category is unknown; use only if potential benefit justifies potential risk
• Conduct periodic ophthalmologic examinations to detect early ocular complications

Humatrope can interact with other medications, requiring attention to avoid adverse outcomes.

Avoid

• Concomitant use of high‑dose glucocorticoids without glucose monitoring
• Simultaneous administration of insulin or oral hypoglycemic agents without adjusting therapy
• Co‑administration with other growth hormone products or somatostatin analogues
• Use with estrogen‑containing therapies that may alter IGF‑1 levels
• Combination with drugs that significantly suppress immune function

Use with caution

• Patients receiving systemic steroids, as they may blunt growth response
• Individuals with diabetes mellitus, requiring close glycemic control
• Patients with active infections, due to potential impact on immune response
• Those on anti‑angiogenic agents, where growth modulation may be relevant
• Patients on medications metabolized by CYP enzymes, although GH has limited direct effect on CYP activity